Education and Dissemination of Nanomedicine in Cancer Core (EDNIC)

核心C4：癌症中纳米药物的教育和传播(EDNIC) 引言 纳米技术，即用大小大致相同的原子和分子簇进行的工作 十亿分之一米，正在市场上出现，并将影响工业的方方面面，改变 面对材料、能源、电子和医疗1纳米级成像试剂将允许临床医生 及早发现疾病，评估治疗效果。重要的是，“纳米”药物可以定制 对所有疾病的治疗。FDA最近批准了一种现有的抗癌药物紫杉醇，它与一种 用于转移性乳腺癌患者的蛋白质纳米颗粒。这种新制剂，紫杉醇，纳米颗粒， 白蛋白结合(Abraxane？，American Pharmtics Partners，Inc.和American Bioscience，Inc.)曾经是 批准于2005.2年1月7日这一最近的批准标志着纳米技术在 医疗保健，更重要的是，在癌症领域。 尽管有望在医学领域取得重大突破，特别是在诊断方面 对于癌症的治疗，纳米科学领域必须克服两个关键挑战。首先也是最重要的， 研究人员必须向社区证明，工程纳米颗粒用于诊断或 癌症的治疗是安全的，不会损害身体或环境。其次，研究人员必须确保 围绕这项技术在癌症中的潜在用途的炒作不会适得其反，如果低于预期的话 使用是成功的。因此，医疗保健专业人员和社区都必须保持良好的 对纳米技术在癌症诊断和治疗中的潜在应用进行了教育。 圣路易斯大都市区，包括密苏里州和伊利诺伊州两州地区的12个县，带来了 纳米医学领域的独特机遇。纳米医学在中国的教育与传播 SCCNE的癌症核心(EDNIC)将利用由 用于此目的的SCC。在这样做的过程中，EDNIC Core不仅将提供对 纳米技术在癌症中的应用，也让我们的社区了解到SCCNE和整个 整个世界。

CORE C4: Education and Dissemination of Nanomedicine in Cancer (EDNIC) Introduction Nanotechnology, the work which takes place with clusters of atoms and molecules approximately the size of a billionth of a meter, is emerging in the marketplace and will impact all aspects of industry, changing the face of materials, energy, electronics, and healthcare.1 Nanoscale imaging agents will allow clinicians to detect disease early and assess effectiveness of treatment. Importantly, "nano-sized" drugs may customize the treatment of all diseases. The FDA recently approved an existing anticancer agent, paclitaxel, bound to a protein nanoparticle for use in patients with metastatic breast cancer. This new agent, paclitaxel, nanoparticle, albumin-bound (Abraxane¿, American Pharmaceutical Partners, Inc. and American Bioscience, Inc.) was approved on January 7, 2005.2 This recent approval marks the beginning of the use of nanotechnology in healthcare, and importantly, in the field of cancer. Despite the promise of dramatic breakthroughs in the field of medicine and, in particular, in the diagnosis and treatment of cancer, the field of nanoscience must overcome two key challenges. First and foremost, researchers must demonstrate to the community that engineered nanoparticles used for the diagnosis or treatment of cancer are safe and will not harm the body or the environment. Second, researchers must ensure that the hype around the potential uses of this technology in cancer will not backfire if fewer than expected uses are successful. Therefore, it is imperative that both healthcare professionals and the community are well educated about the potential uses of nanotechnology in the diagnosis and treatment of cancer. The St. Louis metro area, which encompasses 12 counties in the Missouri and Illinois bi-state area, brings unique opportunities to the field of nanomedicine. The Education and Dissemination of Nanomedicine in Cancer Core (EDNIC) of the SCCNE will utilize many of the educational and informational programs set up by the SCC for this purpose. In doing so, the EDNIC Core will not only provide a basic understanding of nanotechnology in cancer but also inform our community of the work being done at the SCCNE and throughout the world.